维立西呱对HFrEF患者心功能、血清sST2和BNP的影响研究

Effect of villiciguat on cardiac function,serum sST2 and BNP in patients with HFrEF

目的研究维立西呱对射血分数降低性心力衰竭(HFrEF)患者心功能、可溶性人基质裂解素2(sST2)和脑钠肽(BNP)的影响。方法选取2022年7-12月重庆市红十字会医院HFrEF患者108例作为研究对象,根据患者是否使用维立西呱治疗分为观察组(n=48)和对照组(n=60),对照组患者给予HFrEF常规治疗,观察组在对照组基础上联合使用维立西呱治疗,治疗时间为3个月。于治疗前和治疗后检测两组患者超声心动图,血清sST2、BNP水平,比较两组患者治疗期间的不良反应发生率。结果观察组的总有效率高于对照组,差异有统计学意义(93.75%vs.76.67%,P<0.05)。治疗前,两组患者心功能各项指标和血清sST2、BNP水平比较差异无统计学意义(P>0.05);治疗后,两组患者左心房内径(LAD)、左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)及血清sST2、BNP水平均低于治疗前,左心室射血分数(LVEF)高于治疗前,且观察组上述指标均优于对照组,差异有统计学意义(P<0.05)。结论维立西呱可在常规治疗基础上有效提高HFrEF患者疗效,改善患者心功能。

Objective To study the effect of villiciguat on cardiac function,soluble human stromal cleavage 2(sST2)and brain natriuretic peptide(BNP)in patients with heart failure with reduced ejection fraction(HFrEF).Methods A total of 108 patients with HFrEF in Chongqing Red Cross Hospital from July to December 2022 were selected as the research objects.According to whether the patients were treated with villiciguat,they were divided into the observation group(n=48)and control group(n=60).The patients in the control group were treated with HFrEF routine therapy,and the patients in the observation group were treated with villiciguat on the basis of the routine therapy.The treatment time was three months.The echocardiography,levels of serum sST2 and BNP were detected before and after treatment,and the incidence of adverse reactions during treatment was compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(93.75%vs.76.67%,P<0.05).Before treatment,there were no significant differences in cardiac function indexes and serum sST2 and BNP levels between the two groups(P>0.05).After treatment,the left atrial diameter(LAD),left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD),serum sST2 and BNP levels in the two groups were lower than those before treatment,the left ventricular ejection fraction(LVEF)was higher than that before treatment,and the above indexes in the observation group were better than those in the control group,the differences were statistically significant(P<0.05).Conclusion On the basis of routine therapy,villiciguat can effectively improve the curative effect of HFrEF patients and improve the cardiac function of patients.